

**From:** [REDACTED]  
**Subject:** RE: Electronic EC decisions during COVID-19  
**Date:** mardi 20 octobre 2020 18:28:00  
**Attachments:** [image001.png](#)

---

Dear [REDACTED]

The functional mailbox of the team dealing with the notifications is [SG-GREFFE-CERTIFICATION@ec.europa.eu](mailto:SG-GREFFE-CERTIFICATION@ec.europa.eu).

Companies may also request it (together with a justification) with direct reply to the e-mail that they receive from the Secretariat-General after the adoption of the Commission Decision.

Best regards,  
 Florian

---

**From:** [REDACTED]  
**Sent:** Monday, October 19, 2020 8:26 PM  
**To:** [REDACTED]  
**Subject:** RE: Electronic EC decisions during COVID-19

Dear [REDACTED]

Thank you very much for this recommendation.

Would there be any specific contact person or e-mail address of the Secretariat-General which companies should use?

Best regards,

[REDACTED]

[REDACTED]




---

**From:** [REDACTED]  
**Sent:** 19 October 2020 20:07  
**To:** [REDACTED]  
**Subject:** RE: Electronic EC decisions during COVID-19

Dear [REDACTED]

Thanks a lot for your message. Until further notice and taking into account the current circumstance the Commission will continue with the electronic notification of marketing authorisations. There is currently no plan to resume the issuing of signed paper copies.

However, the Secretariat-General of the Commission, which is responsible for dispatching the Commission decision, informed us that in case of a specific and justified need companies may approach the Secretariat-General to verify the possibility of sending a signed paper copy in an individual case.

With kind regards,

Disclaimer: The above text cannot be regarded as an official position of the European Commission; any views expressed are exclusively those of the author. It is intended solely for the person to whom it is addressed and may contain confidential information. If you received this e-mail in error, please notify us immediately by e-mail or telephone and delete the e-mail without copying or disclosing its contents to any other person.

---

**From:** [REDACTED]  
**Sent:** Friday, October 9, 2020 10:07 AM  
**To:** [REDACTED]  
**Subject:** Electronic EC decisions during COVID-19

Dear [REDACTED]

I am contacting you from EuropaBio with a question that had been raised by us in previous Wednesday morning meetings of the COVID-19 EU Steering Group.  
It concerns the authorisation decisions by the European Commission. Has there already been any decision as to whether the European Commission will start issuing also the signed paper copies of electronic EC Decisions and if so, as of when? This is having an impact in international markets and is a very important issue for the biotech and biopharmaceutical industry.

Many thanks in advance for your consideration.

Best regards,

[REDACTED]  
[REDACTED]  
[REDACTED]  
**EuropaBio** - [REDACTED]  
[REDACTED]



#### Disclaimer

The information contained in this communication from the sender is confidential except for Press Releases. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

We respect the EU General Data Protection Regulation (GDPR) of 14 April 2016. You have the right to unsubscribe from our communications at any moment and ask to be deleted from our database by contacting the sender of this e-mail. All personal data that we gain from personal contacts, mailings and the website are structurally recorded by EuropaBio and is not passed on to third parties. If you want to view your data, you can make a request to EuropaBio, Avenue des Arts 53, 1000 Brussels (Belgium), phone +32 2 739 11 75 or [by e-mail](#). Extra information on data protection can be requested from the Data Protection Commission, Rue de la Presse 35, 1000 Brussels (Belgium), phone: +32 2 213 85 40 – [E-mail](#) - [website](#)

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd**, an innovator in Software as a Service (SaaS) for business. Providing a **safer and more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more [Click Here](#).

## Disclaimer

The information contained in this communication from the sender is confidential except for Press Releases. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

We respect the EU General Data Protection Regulation (GDPR) of 14 April 2016. You have the right to unsubscribe from our communications at any moment and ask to be deleted from our database by contacting the sender of this e-mail. All personal data that we gain from personal contacts, mailings and the website are structurally recorded by EuropaBio and is not passed on to third parties. If you want to view your data, you can make a request to EuropaBio, Avenue des Arts 53, 1000 Brussels (Belgium), phone +32 2 739 11 75 or [by e-mail](#). Extra information on data protection can be requested from the Data Protection Commission, Rue de la Presse 35, 1000 Brussels (Belgium), phone: +32 2 213 85 40 – [E-mail](#) - [website](#)

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd**, an innovator in Software as a Service (SaaS) for business. Providing a **safer** and **more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more [Click Here](#).